NAIC Consumer Representative Carl Schmid speaks at the 2023 NAIC Spring Meeting on a panel about how insurers create barriers to prescription drugs through onerous prior-authorization requirements.
Plan benefit design, prescription drugs, and race
Carl Schmid presents to NAIC Special Committee on Race & Insurance on how insurance benefit design impacts prescription drug access for racial and ethnic communities and suggestions for overcoming access barriers by reducing utilization management measures, lowering cost-sharing, offering standardized plans, and enforcing ACA non-discrimination policies.
Role of state regulators in addressing discriminatory benefit design
Carl Schmid presents at National Association of Insurance Commissioners, along with other consumer representatives, on discrimination in insurance benefit design with a focus on prescription drugs and adverse tiering.
Role of PBMs in patient access & affordability of prescription drugs & potential solutions
HIV+Hep’s Carl Schmid, a consumer representative to the National Association of Insurance Commissioners (NAIC), presents to the NAIC PBM subgroup, along with ACSCAN’s Anna Howard, on how PBM’s impact patient access and affordability of prescription drugs.
Copay Accumulators, State Bans & IRS Issues
HIV+Hep’s Carl Schmid’s presentation before the NAIC Regulatory Framework Task Force on the value of copay assistance for Rx, state laws that ensure copay assistance counts, and ways to mitigate any potential conflicts with those state laws with IRS/Health Savings Account issues.